Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Reducing metastases stiffness by targeting fibroblasts improves therapeutic outcome in colorectal cancer [Cells]

ABSTRACT: Analysis of primary fibroblasts isolated from human colorectal primary tumors(CAFs) and liver metastases(MAFs) and identify corresponding gene expression signatures

ORGANISM(S): Homo sapiens

PROVIDER: GSE145428 | GEO | 2020/05/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Reducing metastases stiffness by targeting fibroblasts improves therapeutic outcome in colorectal cancer [Tissue]

Project description:Analysis of colorectal primary tumors (pTU) and liver metastases (LM) tissue samples from patients and identify corresponding gene expression signatures

2020-05-01 | GSE145429 | GEO

Reducing metastases stiffness by targeting fibroblasts improves therapeutic outcome in colorectal cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-05-01 | GSE145432 | GEO

Reducing metastases stiffness by targeting fibroblasts improves therapeutic outcome in colorectal cancer

Project description:Reducing metastases stiffness by targeting fibroblasts improves therapeutic outcome in colorectal cancer

| PRJNA607204 | ENA

Reducing metastases stiffness by targeting fibroblasts improves therapeutic outcome in colorectal cancer [Tissue]

Project description:Reducing metastases stiffness by targeting fibroblasts improves therapeutic outcome in colorectal cancer [Tissue]

| PRJNA607210 | ENA

Reducing metastases stiffness by targeting fibroblasts improves therapeutic outcome in colorectal cancer [Cells]

Project description:Reducing metastases stiffness by targeting fibroblasts improves therapeutic outcome in colorectal cancer [Cells]

| PRJNA607211 | ENA

Association of microRNAs with colon tumor metastases

2014-08-01 | GSE44121 | GEO

DNA methylation of matched primary-metastases medulloblastomas

Project description:DNA methylation was generated from 11 pairs of matched primary-metastases medulloblastoma samples using the Illumina Infinium HumanMethylation450 BeadChip array Total DNA was extracted from primary and metastases medulloblastoma samples, bisulfite converted and hybridized to Illumina Infinium HumanMethylation450 BeadChip according to the manufacturer's instructions.

2015-04-01 | E-GEOD-63669 | biostudies-arrayexpress

Exploiting ECM signatures associated with human metastases for targeting tumors and metastases using alpaca-derived nanobodies

Project description:Jailkhani N, Clauser KR, Mak H, Rickelt S, Tian C, Whittaker CA, Tanabe KK, Purdy SR, Carr SA, and Hynes RO.2022. Metastases are hard to detect and treat, and cause most cancer-related deaths. The relative lack of therapies targeting metastases represents a major unmet clinical need. The extracellular matrix or ECM forms a major component of the tumor microenvironment in both primary and metastatic tumors and certain ECM proteins can be selectively and abundantly expressed in such tumors. We propose that nanobodies against ECM proteins that show selective abundance in metastases can be used as vehicles for delivery of imaging and therapeutic cargoes. To gain a deeper understanding of the microenvironment of human metastases, we describe here an LC-MS/MS-based ECM signature shared by human TNBC and CRC metastases to different organs and provide evidence that this conserved set of ECM proteins is selectively elevated in other tumors. We also describe phage-display libraries of nanobodies raised against ECM-enriched preparations from human metastases from TNBC and CRC. As proof of concept, we developed selective and specific, high-affinity nanobodies against an example signature protein, Tenascin-C (TNC), known to be abundant in many tumor types and to play a role in metastases. We report that TNC is abundantly expressed in patient metastases and widely expressed across diverse metastatic sites originating from several primary tumor types. Using immuno-PET/CT we showed that anti-TNC nanobodies bind TNBC tumors and metastases with excellent specificity. We propose that such generic anti-tumor nanobodies are promising cancer-agnostic, in vivo tools for the delivery of therapeutics to tumor and metastatic ECM.

2022-03-28 | MSV000089136 | MassIVE

Association of microRNAs with colon tumor metastases

Project description:We compared the expression of microRNAs in primary colon tumors with their paired liver metastases using the Nanostring human microRNA assays version 1 23 microRNAs were found to be differentially expressed between colon primary tumors and their paired metastases Total mRNA was extracted from flash frozen primary colon tumors and paired metastases. 18 tissues from 9 donors were used for this study. 100 ng of RNA was hybridized to Nanostring Human 0microRNA assays version 1.0. Data was normalized according to manufacterer's recommendation. This included background substraction and normalizing to the geometric mean of the highest 75 microRNAs.

2014-08-01 | E-GEOD-44121 | biostudies-arrayexpress

Breast cancer metastases

Project description:We have analysed a unique tumour set of fourteen primary breast cancer tumours with matched synchronous axillary lymph node metastases and a set of nine primary tumours with, later developed, matched distant metastases spread to different sites in the body. The aim was to further understand the molecular changes during the spreading and identify differentially regulated proteins that may be novel biomarkers or treatment targets. We analysed the changes in glycoprotein expression since protein glycosylation is predominant in both membrane proteins and secreted proteins and these proteins are often important for cancer transformation. This may also allow affinity capture enabling selected reaction monitoring of these biomarkers in blood. Glycopeptide capture was used in this study to selectively isolate and quantify N-linked glycopeptides from tumours mixtures and the captured glycopeptides were subjected to label-free quantitative tandem mass spectrometry analysis. Differentially expressed proteins between primary tumours and matched lymph node metastasis and distant metastasis were identified. Two of the top hits, ATPIF1 and tubulin β-chain were validated to be differentially regulated with immunohistochemistry.

2022-02-28 | PXD001637 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data